Abstract

BackgroundIn Thailand, South Africa and Zanzibar, a decrease in malaria morbidity was observed following the introduction of artemisinin-based combination therapy (ACT). In Senegal, therapeutic trials supervised the in vivo efficacy of artesunate plus amodiaquine from 1999 to 2005 at the M'lomp village dispensary. The trends in malaria morbidity in this village were evaluated from 2000 to 2002.MethodsEach year, between July and December inclusive, fevers treated with antimalarials and slide-proven, uncomplicated malaria cases were collected from dispensary health records. Data were also collected in 1998, just prior to ACT introduction. Pearson's chi square tests and Student tests were used to compare two percentages or two means respectively (α = 0.05).ResultsBetween 1998 and 2002, the total number of fevers treated with antimalarials and their repetitiveness progressively decreased: From 2824 to 945 fevers and from 17.6% to 9.7% (RR1998–2002 = 0.55; [0.44–0.69]; p < 0.0001) respectively. Considering uncomplicated malaria cases only, a decrease was observed in their total number between 2001 and 2002, from 953 to 570 cases. The incidence rate and repetitiveness also decreased. The incidence rate fell from 46.1% in 2001 to 37.5% in 2002 (p < 0.0001) and the repetitiveness decreased from 13.0% in 2000 to 6.6% in 2002 (RR2000–2002 = 0.51; [0.35–0.72]; p = 0.0001).ConclusionThe percentage of uncomplicated malaria cases treated with ACT increased, from 18.9% in 2000 to 64.0% in 2002, making it tempting to conclude an impact on malaria morbidity. Nonetheless, the decline in incidence rate of uncomplicated malaria was slight and a lower recorded rainfall was reported in 2002 which could also explain this decline. The context in which ACT is introduced affects the impact on malaria morbidity. In M'lomp, in contrast to studies in Thailand, South Africa and Zanzibar, ACT coverage of malaria cases was low and no vector control measure was deployed. Moreover, the malaria transmission level is higher. In sub-Saharan countries, in order to optimize the impact on malaria morbidity, ACT deployment must be supported, on the one hand, by a strengthening of public health system to ensure a high ACT coverage and, on the other hand, by others measures, such vector control measures.

Highlights

  • IntroductionM'lomp dispensary In 1999, a comparative therapeutic trial of artesunate plus amodiaquine (AS+AQ) versus AQ was carried out to assess the in vivo efficacy and safety of artemisinin-based combination therapy (ACT)

  • Introduction of artemisinin-based combination therapy (ACT) at theM'lomp dispensary In 1999, a comparative therapeutic trial of artesunate plus amodiaquine (AS+AQ) versus AQ was carried out to assess the in vivo efficacy and safety of ACT

  • TnFuoigmtuablreneru1manbdeirnocifdfeenvceersratrteaotef dunwciothmapnlitciamteadlarmiaalsla–riaTcoatsael s Total number of fevers treated with antimalarials – Total number and incidence rate of uncomplicated malaria cases

Read more

Summary

Introduction

M'lomp dispensary In 1999, a comparative therapeutic trial of AS+AQ versus AQ was carried out to assess the in vivo efficacy and safety of ACT. In Senegal, therapeutic trials supervised the in vivo efficacy of artesunate plus amodiaquine from 1999 to 2005 at the M'lomp village dispensary. Since 2001, in the face of the extension of Plasmodium falciparum resistance to commonly used antimalarials, the WHO has advocated the adoption of artemisinin-based combination therapy (ACT) for treating uncomplicated malaria [1]. In camps for displaced persons on the north-western border of Thailand, a 67% reduction in the incidence of malaria was observed in 1997, following of four years use of artesunate plus mefloquine (AS+MQ) [7]. In North A District of Zanzibar, the total annual number of outpatient malaria diagnoses decreased by 67% in children under five years old in 2005, two years after the implementation of artesunate plus amodiaquine (AS+AQ) [10]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.